CAM
LCTX icon

ClariVest Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

ClariVest Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-64,467
Closed -$150K – 748
2018
Q1 		$150K Buy
64,467
+6,265
+11% +$14.7K ﹤0.01% 631
2017
Q4 		$110K Hold
58,202
– – ﹤0.01% 624
2017
Q3 		$145K Buy
58,202
+2,258
+4% +$5.6K ﹤0.01% 520
2017
Q2 		$153K Hold
55,944
– – ﹤0.01% 503
2017
Q1 		$169K Buy
+55,944
New +$159K ﹤0.01% 504

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return